Ozmosi | Prednisone Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Prednisone

Alternative Names: prednisone, decortin, prednison, lodotra, apo-prednisone, rayos, CORTANCYL, orasone, prednisona, deltasone, cortan, liquid pred, delta-dome, meticorten, paracort, fernisone, servisone, prednicen-m, deltasone 5mg, prednimustine
Clinical Status: Inactive
Latest Update: 2026-03-03
Latest Update Note: Clinical Trial Update

Product Description

Prednisone is a synthetic, anti-inflammatory glucocorticoid that derives from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone is an FDA-approved, delayed-release corticosteroid indicated as an anti-inflammatory or immunosuppressive agent to treat a broad range of diseases, including immunosuppressive/endocrine, rheumatic, collagen, dermatologic, allergic states, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, acute exacerbations of multiple sclerosis, and as an anti-inflammatory and an antineoplastic agent.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30521230/)

Mechanisms of Action: GR Agonist, Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: Eastern America
Company Founding Year: 1886
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Prednisone

Countries in Clinic: Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 66

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Asthma, Allergic|Bronchiolitis Obliterans|Conjunctivitis, Allergic|Diffuse Large B-Cell Lymphoma|Drug Hypersensitivity|Erythema Multiforme|Giant Cell Arteritis|Graft vs Host Disease|Histiocytosis|Hodgkin Lymphoma|Kidney Diseases|Kidney Transplant|Lymphoma|Lymphoma, B-Cell|Multiple Myeloma|Other|Pemphigoid, Bullous|Polymyalgia Rheumatica|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prostate Cancer|Pyoderma Gangrenosum|Rhinitis, Allergic|T-Cell Peripheral Lymphoma

Phase 2: Adenocarcinoma|Allogeneic Stem Cell Transplant|Burkitt Lymphoma|COVID-19|Cardiomyopathy, Dilated|Depressive Disorder, Major|Fetal Diseases|Follicular Lymphoma|GM1 Gangliosidosis|Gangliosidoses|Gangliosidosis, GM1|Heart Failure|Lung Cancer|Lymphoma, Non-Hodgkin|Lymphoproliferative Disorders|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Pregnancy Complications, Infectious|Pregnancy Outcomes|Radiation Pneumonitis|T-Cell Leukemia|T-Cell Lymphoma

Phase 1: Acute Myeloid Leukemia|B-Cell Leukemia|Blast Crisis|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2024-516905-22-00

2024-516905-22-00

P3

Active, not recruiting

Multiple Myeloma

2031-12-31

2025-05-02

Treatments

NCT06072131

CRESCENDO

P3

Recruiting

T-Cell Peripheral Lymphoma

2030-07-01

18%

2024-11-27

NCT07097363

RG1125011

P2

Recruiting

T-Cell Lymphoma|Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Burkitt Lymphoma

2030-05-31

12%

2025-12-18

Primary Endpoints|Start Date|Treatments|Trial Status

NCT07412470

FREXERA

P3

Not yet recruiting

Kidney Transplant

2029-08-15

33%

2026-02-18

NCT05848765

REFRACT

P2

Recruiting

Follicular Lymphoma

2029-05-31

78%

2024-11-27

NCT04175431

RG1004972

P2

Recruiting

Adenocarcinoma|Prostate Cancer

2028-07-01

12%

2025-12-19

Primary Completion Date|Primary Endpoints|Study Completion Date

NCT06738368

RG1124788

P2

Recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia|Acute Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Burkitt Lymphoma

2028-01-31

12%

2026-01-31

NCT03952637

19-HG-0101

P2

Recruiting

Gangliosidoses|GM1 Gangliosidosis|Gangliosidosis, GM1

2028-01-01

12%

2025-08-27

Primary Endpoints

NCT06585774

INCA34176-357

P3

Recruiting

Graft vs Host Disease|Bronchiolitis Obliterans

2027-09-28

35%

2024-12-06

Primary Endpoints|Treatments|Trial Status

NCT06954805

AAAV2404

P2

Recruiting

Lymphoma, B-Cell|Lymphoproliferative Disorders

2027-04-14

2025-05-03

Primary Endpoints|Treatments

NCT06624670

U1111-1306-8055

P3

Recruiting

Pyoderma Gangrenosum

2027-04-12

24%

2025-09-20

Primary Completion Date|Primary Endpoints|Study Completion Date

jRCT2033240447

jRCT2033240447

P2

Recruiting

Cardiomyopathy, Dilated|Heart Failure

2027-03-31

NCT03595917

NCT03595917

P1

Recruiting

Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Blast Crisis|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|B-Cell Leukemia|Lymphoma, B-Cell|Burkitt Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia

2026-11-01

12%

2025-11-05

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT03117751

TOT17

P3

Active, not recruiting

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2026-09-30

10%

2024-11-27

Primary Endpoints|Treatments

NCT02684708

EuroNet-PHL-C2

P3

Active, not recruiting

Hodgkin Lymphoma

2026-09-30

2021-05-14

Primary Endpoints|Treatments|Trial Status

2024-511383-88-00

SC-3C2A

P3

Active, not recruiting

Asthma, Allergic|Rhinitis, Allergic|Conjunctivitis, Allergic

2026-09-30

2025-05-02

Treatments

NCT04980222

GO43075

P2

Active, not recruiting

Lymphoma

2026-09-30

12%

2025-11-19

Primary Completion Date|Primary Endpoints|Treatments

2023-508614-41-00

2023-0038

P2

Recruiting

Allogeneic Stem Cell Transplant

2026-09-01

2025-05-02

Treatments

2022-000712-59

SEM-CORTICO (Severe Erythema Multiforme - CORTICO)

P3

Active, not recruiting

Erythema Multiforme

2026-08-07

NCT04812366

GUNS

P2

Recruiting

Prostate Cancer

2026-04-01

12%

2022-02-08

Primary Endpoints|Treatments

NCT06172361

ITTGPMR

P3

Recruiting

Polymyalgia Rheumatica|Giant Cell Arteritis

2025-09-30

2024-07-30

Primary Endpoints|Start Date|Treatments|Trial Status

NCT05267600

BALLAD

P3

Completed

Pemphigoid, Bullous

2024-09-13

57%

2024-10-16

Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status

NCT02496585

NCT02496585

P2

Completed

Radiation Pneumonitis|Lung Cancer

2024-04-12

24%

2025-08-27

Primary Endpoints|Treatments

NCT05288166

CYCLONE 3

P3

Active, not recruiting

Drug Hypersensitivity|Prostate Cancer

2024-02-15

17%

2025-06-28

2017-000390-37

MASTER-ANCA

P3

Active, not recruiting

Kidney Diseases

2023-12-01

2022-03-13

Treatments